Cytokinetics Heart Failure Drug Needs Another Phase III Study, US FDA Panel Says

Additional trial of omecamtiv mecarbil should be focused on the narrower group of heart failure patients that the initial Phase III study seemed to suggest may have a favorable risk-benefit calculus with the drug, Cardiovascular and Renal Drugs Advisory Committee members told FDA.

heart
Advisory panel says Cryokinetics needs to do more study for a narrower indication • Source: Shutterstock

Cytokinetics, Inc.’s heart failure treatment omecamtiv mecarbil looks to be headed for a complete response letter following a US Food and Drug Administration advisory panel recommendation that the company conduct a second Phase III study of the drug.

The Cardiovascular and Renal Drugs Advisory Committee voted 8-3 on 13 December that the benefits of the drug do not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA Performance Tracker

More from Regulatory Trackers